Histamine ameliorates anti-glomerular basement membrane antibody-induced glomerulonephritis in rats. 2007

S Tanda, and Y Mori, and T Kimura, and K Sonomura, and T Kusaba, and N Kishimoto, and H Kameyama, and K Tamagaki, and M Okigaki, and T Hatta, and S Sasaki, and K Takeda, and Y Sado, and N Adachi, and H Matsubara
Division of Cardiology and Nephrology, Department of Medicine, Kyoto Prefectural University of Medicine, Kajii-cho 465, Kawaramachi Hirokoji, Kyoto 602-8566, Japan. standa@koto.kpu-m.ac.jp

Anti-glomerular basement membrane (anti-GBM)-induced glomerulonephritis involves T-helper type 1 (Th1) responses leading to rapid crescent formation. As many inflammatory and immune responses in general are affected by histamine, we examined the effects of histaminergic ligands on immune renal injury in the rat. Female Wistar-Kyoto rats were injected intraperitoneally with an antibody against the GBMs. Histaminergic ligands were then injected twice daily for 5 days after which renal function was assessed by proteinuria. Treatment with histamine led to significant dose-dependent reductions in proteinuria compared to the control antibody-injected group and markedly decreased the number of crescentic glomeruli and macrophage infiltration of the glomeruli. Furthermore, histamine significantly decreased the plasma concentration of interleukin-12, a Th1-type cytokine compared to the antibody-injected control animals. Dimaprit, an H(2)/H(4) agonist, mimicked the effects of histamine on proteinuria and crescent formation. Clozapine, an H(4) agonist, tended to mimic the effects of histamine, whereas an H(1), mepyramine, or an H(2) antagonist, ranitidine, did not reverse the protective effect of histamine. We suggest that histamine may alleviate renal injury in anti-GBM glomerulonephritis by suppressing the immune response.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D011507 Proteinuria The presence of proteins in the urine, an indicator of KIDNEY DISEASES. Proteinurias
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D005260 Female Females
D005921 Glomerulonephritis Inflammation of the renal glomeruli (KIDNEY GLOMERULUS) that can be classified by the type of glomerular injuries including antibody deposition, complement activation, cellular proliferation, and glomerulosclerosis. These structural and functional abnormalities usually lead to HEMATURIA; PROTEINURIA; HYPERTENSION; and RENAL INSUFFICIENCY. Bright Disease,Kidney Scarring,Glomerulonephritides,Scarring, Kidney
D006632 Histamine An amine derived by enzymatic decarboxylation of HISTIDINE. It is a powerful stimulant of gastric secretion, a constrictor of bronchial smooth muscle, a vasodilator, and also a centrally acting neurotransmitter. Ceplene,Histamine Dihydrochloride,Histamine Hydrochloride,Peremin
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000906 Antibodies Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).

Related Publications

S Tanda, and Y Mori, and T Kimura, and K Sonomura, and T Kusaba, and N Kishimoto, and H Kameyama, and K Tamagaki, and M Okigaki, and T Hatta, and S Sasaki, and K Takeda, and Y Sado, and N Adachi, and H Matsubara
February 1973, Kidney international,
S Tanda, and Y Mori, and T Kimura, and K Sonomura, and T Kusaba, and N Kishimoto, and H Kameyama, and K Tamagaki, and M Okigaki, and T Hatta, and S Sasaki, and K Takeda, and Y Sado, and N Adachi, and H Matsubara
January 1996, Japanese journal of pharmacology,
S Tanda, and Y Mori, and T Kimura, and K Sonomura, and T Kusaba, and N Kishimoto, and H Kameyama, and K Tamagaki, and M Okigaki, and T Hatta, and S Sasaki, and K Takeda, and Y Sado, and N Adachi, and H Matsubara
April 1988, British journal of experimental pathology,
S Tanda, and Y Mori, and T Kimura, and K Sonomura, and T Kusaba, and N Kishimoto, and H Kameyama, and K Tamagaki, and M Okigaki, and T Hatta, and S Sasaki, and K Takeda, and Y Sado, and N Adachi, and H Matsubara
January 1990, Japanese journal of medicine,
S Tanda, and Y Mori, and T Kimura, and K Sonomura, and T Kusaba, and N Kishimoto, and H Kameyama, and K Tamagaki, and M Okigaki, and T Hatta, and S Sasaki, and K Takeda, and Y Sado, and N Adachi, and H Matsubara
June 2012, Kidney international supplements,
S Tanda, and Y Mori, and T Kimura, and K Sonomura, and T Kusaba, and N Kishimoto, and H Kameyama, and K Tamagaki, and M Okigaki, and T Hatta, and S Sasaki, and K Takeda, and Y Sado, and N Adachi, and H Matsubara
January 1994, The Journal of clinical investigation,
S Tanda, and Y Mori, and T Kimura, and K Sonomura, and T Kusaba, and N Kishimoto, and H Kameyama, and K Tamagaki, and M Okigaki, and T Hatta, and S Sasaki, and K Takeda, and Y Sado, and N Adachi, and H Matsubara
November 2023, The New England journal of medicine,
S Tanda, and Y Mori, and T Kimura, and K Sonomura, and T Kusaba, and N Kishimoto, and H Kameyama, and K Tamagaki, and M Okigaki, and T Hatta, and S Sasaki, and K Takeda, and Y Sado, and N Adachi, and H Matsubara
December 1996, European journal of pharmacology,
S Tanda, and Y Mori, and T Kimura, and K Sonomura, and T Kusaba, and N Kishimoto, and H Kameyama, and K Tamagaki, and M Okigaki, and T Hatta, and S Sasaki, and K Takeda, and Y Sado, and N Adachi, and H Matsubara
September 1995, The American journal of physiology,
S Tanda, and Y Mori, and T Kimura, and K Sonomura, and T Kusaba, and N Kishimoto, and H Kameyama, and K Tamagaki, and M Okigaki, and T Hatta, and S Sasaki, and K Takeda, and Y Sado, and N Adachi, and H Matsubara
February 1980, Clinical nephrology,
Copied contents to your clipboard!